Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

$316.2M Raised — Spyre Therapeutics Closes 17.09M-Share Public Offering, Underwriters Exercised

Spyre Therapeutics Closes $316.2 Million Public Offering of Common Stock

Spyre Therapeutics Prices $275 Million Share Offering

Spyre Therapeutics Stock Rises 11% After $275 Mln Public Offering Pricing

Spyre Therapeutics falls after stock offering launch